Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA264187
Max Phase: Preclinical
Molecular Formula: C50H77NO14
Molecular Weight: 916.16
Molecule Type: Small molecule
Associated Items:
ID: ALA264187
Max Phase: Preclinical
Molecular Formula: C50H77NO14
Molecular Weight: 916.16
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CCC(C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@H](NC(C)=O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2
Standard InChI: InChI=1S/C50H77NO14/c1-12-26(2)45-29(5)18-19-49(65-45)24-36-21-35(64-49)17-16-28(4)44(27(3)14-13-15-34-25-58-47-43(53)30(6)20-37(48(54)61-36)50(34,47)55)62-41-23-39(57-11)46(32(8)60-41)63-40-22-38(56-10)42(31(7)59-40)51-33(9)52/h13-16,20,26-27,29,31-32,35-47,53,55H,12,17-19,21-25H2,1-11H3,(H,51,52)/b14-13+,28-16+,34-15+/t26?,27-,29-,31-,32-,35+,36-,37-,38-,39-,40-,41-,42+,43+,44-,45+,46-,47+,49+,50+/m0/s1
Standard InChI Key: RFOFCINIEFWCGQ-BTUYMBSXSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 916.16 | Molecular Weight (Monoisotopic): 915.5344 | AlogP: 5.75 | #Rotatable Bonds: 9 |
Polar Surface Area: 178.93 | Molecular Species: NEUTRAL | HBA: 14 | HBD: 3 |
#RO5 Violations: 3 | HBA (Lipinski): 15 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 12.49 | CX Basic pKa: | CX LogP: 5.54 | CX LogD: 5.54 |
Aromatic Rings: 0 | Heavy Atoms: 65 | QED Weighted: 0.19 | Np Likeness Score: 2.25 |
1. Mrozik H, Eskola P, Arison BH, Linn BO, Lusi A, Matzuk A, Shih TL, Tischler M, Waksmunski FS, Wyvratt MJ, Blizzard TA, Margiatto GM, Fisher MH, Shoop WL, Egerton JR. (1995) 4-Deoxy-4-aminoavermectins with potent broad spectrum antiparasitic activities, 5 (20): [10.1016/0960-894X(95)00424-R] |
Source(1):